文献速递腹部技术与安全MR

利用钆塞酸增强MRI估算单发肝细胞癌患者术后结局:风险评分系统的开发与验证

Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: risk scoring system development and validation.
PubMed 文献 · Eur Radiol · 2023-03-18

该研究回顾性纳入两个中心295例接受根治性手术的单发初治肝细胞癌患者,基于钆塞酸增强肝脏MRI特征和临床因素开发并外部验证预测无复发生存的风险评分系统;验证集C指数0.75-0.82,优于BCLC(0.61)和AJCC(0.58)分期系统;术前评分系统将患者分为低、中、高危组,验证集2年复发率分别为3.3%、31.8%、85.7%。

要点

  • 术前评分系统纳入肿瘤大小、靶样表现、影像学脉管侵犯、肝胆期非富血供低信号结节及肿瘤标志物。
  • 验证集C指数0.75-0.82,优于BCLC分期0.61和AJCC分期0.58(ps<0.05)。
  • 术前评分低、中、高危组验证集2年复发率分别为3.3%、31.8%、85.7%。

核心结论

  • 开发并验证的术前和术后风险评分系统可估算单发肝细胞癌术后无复发生存。

研究设计与样本

  • 回顾性研究,两个中心连续纳入295例接受根治性手术的初治单发肝细胞癌患者,使用钆塞酸增强肝脏MRI特征和临床因素,以Cox比例风险模型开发风险评分系统,并用外部数据验证。

关键影像表现/征象

  • 靶样表现与无复发生存独立相关(HR 1.74,95%CI 1.07-2.83,p=0.025)。
  • 影像学脉管内癌栓或肿瘤血管侵犯与无复发生存独立相关(HR 2.59,95%CI 1.69-3.97,p<0.001)。
  • 肝胆期存在非富血供低信号结节与无复发生存独立相关(HR 4.65,95%CI 3.03-7.14,p<0.001)。
  • 病理大血管侵犯与无复发生存独立相关(HR 2.60,95%CI 1.51-4.48,p=0.001)。
  • 肿瘤大小每增加1 cm与无复发生存独立相关(HR 1.07,95%CI 1.02-1.13,p=0.005)。

诊断标准与关键数值

  • 风险评分系统纳入变量:肿瘤大小(每cm,HR 1.07,95%CI 1.02-1.13,p=0.005)、靶样表现(HR 1.74,95%CI 1.07-2.83,p=0.025)、影像学脉管内癌栓或肿瘤血管侵犯(HR 2.59,95%CI 1.69-3.97,p<0.001)、肝胆期非富血供低信号结节(HR 4.65,95%CI 3.03-7.14,p<0.001)、病理大血管侵犯(HR 2.60,95%CI 1.51-4.48,p=0.001),联合肿瘤标志物(AFP≥206 ng/mL或PIVKA-II≥419 mAU/mL)。
  • 验证集C指数0.75-0.82,优于BCLC分期0.61和AJCC分期0.58(ps<0.05)。
  • 术前评分系统将患者分为低、中、高危组,验证集2年复发率分别为3.3%、31.8%、85.7%。

临床应用与阅片要点

  • 可依据肿瘤大小、靶样表现、影像学脉管侵犯、肝胆期非富血供低信号结节及肿瘤标志物进行术前风险分层。
  • 术后评分系统纳入病理大血管侵犯,可用于术后无复发生存估算。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop and validate risk scoring systems using gadoxetic acid-enhanced liver MRI features and clinical factors that predict recurrence-free survival (RFS) of a single hepatocellular carcinoma (HCC).

METHODS: Consecutive 295 patients with treatment-naïve single HCC who underwent curative surgery were retrospectively enrolled from two centers. Cox proportional hazard models developed risk scoring systems whose discriminatory powers were validated using external data and compared to the Barcelona Clinic Liver Cancer (BCLC) or American Joint Committee on Cancer (AJCC) staging systems using Harrell's C-index.

RESULTS: Independent variables-tumor size (per cm; hazard ratio [HR], 1.07; 95% confidence interval [CI]: 1.02-1.13; p = 0.005), targetoid appearance (HR, 1.74; 95% CI: 1.07-2.83; p = 0.025), radiologic tumor in vein or tumor vascular invasion (HR, 2.59; 95% CI: 1.69-3.97; p < 0.001), the presence of a nonhypervascular hypointense nodule on the hepatobiliary phase (HR, 4.65; 95% CI: 3.03-7.14; p < 0.001), and pathologic macrovascular invasion (HR, 2.60; 95% CI: 1.51-4.48; p = 0.001)-with tumor markers (AFP ≥ 206 ng/mL or PIVKA-II ≥ 419 mAU/mL) derived pre- and postoperative risk scoring systems. The risk scores showed comparably good discriminatory powers in the validation set (C-index, 0.75-0.82) and outperformed the BCLC (C-index, 0.61) and AJCC staging systems (C-index, 0.58; ps < 0.05). The preoperative scoring system stratified the patients into low-, intermediate-, and high-risk for recurrence, whose 2-year recurrence rate was 3.3%, 31.8%, and 85.7%, respectively.

CONCLUSION: The developed and validated pre- and postoperative risk scoring systems can estimate RFS after surgery for a single HCC.

KEY POINTS: • The risk scoring systems predicted RFS better than the BCLC and AJCC staging systems (C-index, 0.75-0.82 vs. 0.58-0.61; ps < 0.05). • Five variables-tumor size, targetoid appearance, radiologic tumor in vein or vascular invasion, the presence of a nonhypervascular hypointense nodule on the hepatobiliary phase, and pathologic macrovascular invasion-combined with tumor markers derived risk scoring systems predicting postsurgical RFS for a single HCC. • In the risk scoring system using preoperatively-available factors, patients were classified into three distinct risk groups, with 2-year recurrence rates in the low-, intermediate-, and high-risk groups being 3.3%, 31.8%, and 85.7% in the validation set.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Park SH, Kim B, Kim S, et al. Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: risk scoring system development and validation. Eur Radiol. 2023. PMID: 36933020. doi:10.1007/s00330-023-09539-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。